CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 103 enrolled
Drug / intervention
AZD1386 +2 moredrug
Likely dose
AZD1386 95mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00672646
NCT00672646Phase 2Completed
CompareCT.gov

A Double-blind, Randomized, Placebo and Naproxen Controlled Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386, in Patients Undergoing Impacted Mandibular Third Molar Extraction

AstraZeneca·interventional·Posted May 6, 2008·Updated Jun 8, 2012

In Brief

A Phase 2 clinical trial evaluating AZD1386, Naproxen, and 1 other intervention for Pain. Completed, enrolled 103 participants across 1 site.

Detailed Summary

The primary aim of this study is to investigate if AZD1386 can relieve the pain induced by the surgical removal of one lower wisdom-tooth. This will be done by comparing the effect of AZD1386 to placebo ("inactive substance") on pain. A number of patients will instead receive the common painkiller naproxen for comparison purposes. Rescue medication, acetaminophen, will be allowed if a need for additional painkillers would arise. A number of patients will receive naproxen as control.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 6, 2008
Enrollment StartApr 1, 2008
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 18.2 years ago

Interventions

AZD1386drug

95mg, oral solution, single dose

Naproxendrug

500mg, capsule, single dose

Placebodrug

AZD1386 Placebo oral solution